Huang Kewu, Wang Wenjun, Wang Ying, Li Yanming, Feng Xiaokai, Shen Huahao, Wang Chen
Department of Pulmonary and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing Institute of Respiratory Medicine, Beijing, China.
Department of Pulmonary and Critical Care Medicine, Beijing Hospital, Beijing, China.
JMIR Res Protoc. 2025 Jan 8;14:e65197. doi: 10.2196/65197.
Poor symptom control and exacerbations of asthma diminish quality of life and pose a significant burden to patients and society. Implementing evidence-based management as recommended by the Global Initiative for Asthma (GINA), especially introducing inhaled corticosteroid-containing treatments, has the potential to vastly reduce exacerbations and the high burden of asthma in China. However, domestic implementation of the GINA recommendations has been unsatisfactory, especially in lower-level hospitals; thus, an enhancement to the awareness of and adherence to the GINA recommendations among Chinese physicians is needed to improve patient outcomes.
This study aims to bridge the gap between the GINA recommendations and the current clinical practice in China by demonstrating the benefits of an asthma quality improvement program (QIP).
A single-arm study will be conducted at around 30 hospitals across China to assess the impact of a specially designed asthma QIP. Approximately 1500 patients with asthma aged ≥14 years will be enrolled in participating hospitals and followed up for 48 weeks. The QIP-targeted at all pulmonologists and specialist nurses-will include an initial comprehensive training (including a pretraining questionnaire and posttraining quizzes) provided by a dedicated, qualified training team based on the GINA 2021 recommendations, followed by regular reinforcement learnings (integrated into the regular department lectures delivered by department directors), with multiple offline and online approaches (eg, an online patient management platform) provided as supportive tools. During this study, GINA implementation performance will be continuously monitored to inform necessary adjustments at the hospital level. The primary end point is change from baseline in the proportion of participants with an inhaled corticosteroid-based maintenance or reliever treatment at week 48. Secondary end points and exploratory end points include changes in clinical practice and patient outcomes such as treatment patterns, asthma control, and hospitalization rates due to exacerbations.
This study has been completed, with 1500 patients enrolled and 1271 patients completing the study. The last visit of the last patient was on September 3, 2024, and the database lock was on September 28, 2024. Final analysis of data has started in October 2024.
The Change Asthma Clinical Practice through GINA Education and Implementation for All Patients With Asthma (CARE4ALL) study will hopefully help improve asthma management and patient outcomes in China by bridging the gap between evidence-based GINA recommendations and the current clinical practice.
ClinicalTrials.gov NCT05440097; https://clinicaltrials.gov/study/NCT05440097.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/65197.
哮喘症状控制不佳和病情加重会降低生活质量,给患者和社会带来沉重负担。按照全球哮喘防治创议(GINA)的建议实施循证管理,尤其是引入含吸入性糖皮质激素的治疗方法,有可能大幅减少中国哮喘的病情加重情况和沉重负担。然而,GINA建议在国内的实施情况并不理想,在基层医院尤为如此;因此,需要提高中国医生对GINA建议的认识和依从性,以改善患者预后。
本研究旨在通过展示哮喘质量改进项目(QIP)的益处,弥合GINA建议与中国当前临床实践之间的差距。
将在中国约30家医院开展一项单臂研究,以评估专门设计的哮喘QIP的影响。约1500名年龄≥14岁的哮喘患者将在参与研究的医院入组,并随访48周。针对所有肺科医生和专科护士的QIP将包括由专业合格的培训团队根据GINA 2021建议提供的初始综合培训(包括培训前问卷和培训后测验),随后进行定期强化学习(纳入科室主任定期开展的科室讲座中),并提供多种线下和线上方法(如在线患者管理平台)作为支持工具。在本研究期间,将持续监测GINA实施情况,以便在医院层面进行必要调整。主要终点是第48周时接受基于吸入性糖皮质激素维持或缓解治疗的参与者比例相对于基线的变化。次要终点和探索性终点包括临床实践和患者预后的变化,如治疗模式、哮喘控制情况以及因病情加重导致的住院率。
本研究已完成,共纳入1500例患者,1271例患者完成研究。最后一名患者的末次访视时间为2024年9月3日,数据库锁定时间为2024年9月28日。2024年10月已开始对数据进行最终分析。
通过对所有哮喘患者进行GINA教育与实施来改变哮喘临床实践(CARE4ALL)研究有望通过弥合基于循证的GINA建议与当前临床实践之间的差距,帮助改善中国的哮喘管理和患者预后。
ClinicalTrials.gov NCT05440097;https://clinicaltrials.gov/study/NCT05440097。
国际注册报告识别码(IRRID):DERR1-10.2196/65197。